Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 93Active not recruiting 57Completed 14Not yet recruiting 8Terminated 5Withdrawn 1Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Oropharyngeal Neoplasms 1Carcinoma 1

Interventions

Specimen Handling 21Biopsy 14Magnetic Resonance Spectroscopy 13Cyclophosphamide 4Nivolumab 3Cetuximab 3Azacitidine 3venetoclax 2trastuzumab deruxtecan 2decitabine and cedazuridine drug combination 2X-Rays 2Vincristine 2Taxes 2Surgical Procedures, Operative 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Prednisone 2Practice Guidelines as Topic 2Lenalidomide 2Ipilimumab 2Etoposide 2Doxorubicin 2CTLA-4 Antigen 2(225)Ac-DOTA-c(RGDyK) 2spartalizumab 1relatlimab 1prednylidene 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Cisplatin × 30 days × Clear all
NCT05050162 2026-05-07

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

NRG Oncology

Phase 2/3 Suspended
1,714 enrolled
Head & Neck

Carcinoma, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡